HDAC2 Dysregulation in the Nucleus Basalis of Meynert During the Progression of Alzheimer's Disease

Overview

Journal Neuropathol Appl Neurobiol

Specialty Neurology

Date 2018 Sep 26

PMID 30252960

Citations 25

Authors

L Mahady

M Nadeem

M Malek-Ahmadi

K Chen

S E Perez

E J Mufson

Affiliations

Soon will be listed here.

Abstract

Aims: Alzheimer's disease (AD) is characterized by degeneration of cholinergic basal forebrain (CBF) neurons in the nucleus basalis of Meynert (nbM), which provides the major cholinergic input to the cortical mantle and is related to cognitive decline in patients with AD. Cortical histone deacetylase (HDAC) dysregulation has been associated with neuronal degeneration during AD progression. However, whether HDAC alterations play a role in CBF degeneration during AD onset is unknown. We investigated global HDAC protein levels and nuclear HDAC2 immunoreactivity in tissue containing the nbM, changes and their association with neurofibrillary tangles (NFTs) during the progression of AD.

Methods: We used semi-quantitative western blotting and immunohistochemistry to evaluate HDAC and sirtuin (SIRT) levels in individuals that died with a premortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), mild/moderate AD (mAD) or severe AD (sAD). Quantitative immunohistochemistry was used to identify HDAC2 protein levels in individual cholinergic nbM nuclei and their colocalization with the early phosphorylated tau marker AT8, the late-stage apoptotic tau marker TauC3 and Thioflavin-S, a marker of β-pleated sheet structures in NFTs.

Results: In AD patients, HDAC2 protein levels were dysregulated in the basal forebrain region containing cholinergic neurons of the nbM. HDAC2 nuclear immunoreactivity was reduced in individual cholinergic nbM neurons across disease stages. HDAC2 nuclear reactivity correlated with multiple cognitive domains and with NFT formation.

Conclusions: These findings suggest that HDAC2 dysregulation contributes to cholinergic nbM neuronal dysfunction, NFT pathology, and cognitive decline during clinical progression of AD.

Citing Articles

Histone Deacetylation in Alzheimer's Diseases (AD); Hope or Hype.

Ateya N, Al-Taie S, Jasim S, Uthirapathy S, Chaudhary K, Rani P Cell Biochem Biophys. 2025; .

PMID: 39825060 DOI: 10.1007/s12013-025-01670-0.

Early differential impact of MeCP2 mutations on functional networks in Rett syndrome patient-derived human cerebral organoids.

Osaki T, Delepine C, Osako Y, Kranz D, Levin A, Nelson C bioRxiv. 2024; .

PMID: 39149328 PMC: 11326256. DOI: 10.1101/2024.08.10.607464.

Role of histone deacetylase inhibitors in non-neoplastic diseases.

Zhou C, Zhao D, Wu C, Wu Z, Zhang W, Chen S Heliyon. 2024; 10(13):e33997.

PMID: 39071622 PMC: 11283006. DOI: 10.1016/j.heliyon.2024.e33997.

Study of the multitarget mechanism of (HUANGQI) in the treatment of Alzheimer's disease based on network pharmacology and molecular docking technology.

Lv F, Sun M, Qin C, Du D, Zheng X, Li W Pharm Biol. 2024; 62(1):634-647.

PMID: 39066667 PMC: 11285284. DOI: 10.1080/13880209.2024.2382962.

Oxyresveratrol-β-cyclodextrin mitigates streptozotocin-induced Alzheimer's model cognitive impairment, histone deacetylase activity in rats: in silico & in vivo studies.

Agarwal T, Manandhar S, B H, Famurewa A, Gurram P, Suggala R Sci Rep. 2024; 14(1):9897.

PMID: 38688962 PMC: 11061296. DOI: 10.1038/s41598-024-57188-7.

References

Mufson E, Chen E, Cochran E, Beckett L, Bennett D, Kordower J . Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999; 158(2):469-90. DOI: 10.1006/exnr.1999.7086. View

Iraizoz I, Guijarro J, Gonzalo L, de Lacalle S . Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia. Acta Neuropathol. 1999; 98(2):186-96. DOI: 10.1007/s004010051068. View

Newell K, Hyman B, Growdon J, Hedley-Whyte E . Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1999; 58(11):1147-55. DOI: 10.1097/00005072-199911000-00004. View

Sassin I, Schultz C, Thal D, Rub U, Arai K, Braak E . Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol. 2000; 100(3):259-69. DOI: 10.1007/s004019900178. View

Mufson E, Ma S, Cochran E, Bennett D, Beckett L, Jaffar S . Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 2000; 427(1):19-30. DOI: 10.1002/1096-9861(20001106)427:1<19::aid-cne2>3.0.co;2-a. View

Mufson E, Ma S, Dills J, Cochran E, Leurgans S, Wuu J . Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol. 2002; 443(2):136-53. DOI: 10.1002/cne.10122. View

DeKosky S, Ikonomovic M, Styren S, Beckett L, Wisniewski S, Bennett D . Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002; 51(2):145-55. DOI: 10.1002/ana.10069. View

Wilson R, Beckett L, Barnes L, Schneider J, Bach J, Evans D . Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002; 17(2):179-93. View

Bennett D, Wilson R, Schneider J, Evans D, Beckett L, Aggarwal N . Natural history of mild cognitive impairment in older persons. Neurology. 2002; 59(2):198-205. DOI: 10.1212/wnl.59.2.198. View

10.

Yang Y, Mufson E, Herrup K . Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003; 23(7):2557-63. PMC: 6742098. View

11.

Garcia-Sierra F, Ghoshal N, Quinn B, Berry R, Binder L . Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimers Dis. 2003; 5(2):65-77. DOI: 10.3233/jad-2003-5201. View

12.

DeKosky S, Harbaugh R, Schmitt F, Bakay R, Chui H, Knopman D . Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann Neurol. 1992; 32(5):625-32. DOI: 10.1002/ana.410320505. View

13.

Mesulam M, Shaw P, Mash D, Weintraub S . Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004; 55(6):815-28. DOI: 10.1002/ana.20100. View

14.

Peng S, Wuu J, Mufson E, Fahnestock M . Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol. 2004; 63(6):641-9. DOI: 10.1093/jnen/63.6.641. View

15.

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

16.

Counts S, Nadeem M, Wuu J, Ginsberg S, Saragovi H, Mufson E . Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol. 2004; 56(4):520-31. DOI: 10.1002/ana.20233. View

17.

Johnson G, Stoothoff W . Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci. 2004; 117(Pt 24):5721-9. DOI: 10.1242/jcs.01558. View

18.

Binder L, Guillozet-Bongaarts A, Garcia-Sierra F, Berry R . Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta. 2004; 1739(2-3):216-23. DOI: 10.1016/j.bbadis.2004.08.014. View

19.

Guillozet-Bongaarts A, Garcia-Sierra F, Reynolds M, Horowitz P, Fu Y, Wang T . Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging. 2005; 26(7):1015-22. DOI: 10.1016/j.neurobiolaging.2004.09.019. View

20.

Bennett D, Schneider J, Bienias J, Evans D, Wilson R . Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005; 64(5):834-41. DOI: 10.1212/01.WNL.0000152982.47274.9E. View